英文名稱 | Anti-Human IGF1RxHer3 Bispecific Antibody (Istiratumab; MM 141; MM-005) |
---|---|
中文名稱 | 艾司妥單抗 |
CAS號 | 1509928-04-4 |
英文名稱 | Anti-Human IGF1RxHer3 Bispecific Antibody (Istiratumab; MM 141; MM-005) |
---|---|
中文名稱 | 艾司妥單抗 |
CAS號 | 1509928-04-4 |
Istiratumab, a bispecific mAb against IGF-1R and ErbB3, promotes receptor degradation via proteasomes, inhibiting AKT in pancreatic cancer cells and blocking PI3K/MAPK in ovarian cancer. It enhances chemo efficacy, potentiating paclitaxel, cisplatin, and doxorubicin in preclinical studies.
PMID: 31912800 DOI: 10.1016/j.annonc.2019.09.004
PMID: 29549161 DOI: 10.1158/1078-0432.CCR-17-2262
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
PMID: 31728045 PMCID: PMC6856132 DOI: 10.1038/s41598-019-53322-y